International Orthopaedics

, Volume 31, Issue 6, pp 729–734 | Cite as

A comprehensive clinical review of recombinant human bone morphogenetic protein-2 (INFUSE® Bone Graft)

  • William F. McKay
  • Steven M. Peckham
  • Jeffrey M. Badura
Review

Abstract

The combination of recombinant human bone morphogenetic protein-2 (rhBMP-2) on an absorbable collagen sponge (ACS) carrier has been shown to induce bone formation in a number of preclinical and clinical investigations. In 2002, rhBMP-2/ACS at a 1.5-mg/cc concentration (INFUSE® Bone Graft, Medtronic Spinal and Biologics, Memphis, TN) was FDA-approved as an autograft replacement for certain interbody spinal fusion procedures. In 2004, INFUSE® Bone Graft was approved for open tibial fractures with an intermedullary (IM) nail fixation. Most recently, in March 2007, INFUSE® Bone Graft was approved as an alternative to autogenous bone grafts for sinus augmentations, and for localised alveolar ridge augmentations for defects associated with extraction sockets. The culmination of extensive preclinical and clinical research and three FDA approvals makes rhBMP-2 one of the most studied, published and significant advances in orthopaedics. This review article summarises a number of clinical findings of rhBMP-2/ACS, including the FDA-approved investigational device exemption (IDE) studies used in gaining the aforementioned approvals.

Résumé

L’utilisation de la BMP (rhBPM-2) sur une éponge de collagène a des effets positifs sur l’ostéogénèse. En 2002, ce produit avec un dosage de 1.5 mg/cc (INFUSE® Bone Graft, Medtronic Spinal and Biologics, Memphis, Tenn), a été approuvé par la FDA comme un supplétif de l’auto greffe pour, certains cas d’arthrodèses rachidiennes. En 2004 ce produit (INFUSE®) a également été approuvé par la FDA pour les fractures ouvertes de jambes, traitées par clous centro-médullaires. De façon plus récente, en mars 2007, ce produit a été également autorisé comme une alternative au traitement des ostéolyses et défects osseux associés à l’ablation d’une cupule cotyloïdienne. L’association de ces autorisations et des recherches cliniques et pré-cliniques sur la rhBMP-2 permettent une avance significative des connaissances en chirurgie orthopédique ainsi que la revue des différents travaux et des autorisations de la FDA.

References

  1. 1.
    Baskin DS, Ryan P, Sonntag V, Westmark R, Widmayer MA (2003) A prospective, randomized, controlled cervical fusion study using recombinant human bone morphogenetic protein-2 with the CORNERSTONE-SR allograft ring and the ATLANTIS anterior cervical plate. Spine 28(12):1219–1225PubMedCrossRefGoogle Scholar
  2. 2.
    BESTT Study Group, Govender S, Csimma C, Genant HK, Valentin-Opran A et al (2002) Recombinant human bone morphogenetic protein-2 for treatment of open tibial fractures: a prospective, controlled, randomized study of four hundred and fifty patients. J Bone Joint Surg Am 84(12):2123–2134PubMedGoogle Scholar
  3. 3.
    Boyne PJ, Marx RE, Nevins M, Triplett G, Lazaro E, Lilly LC, Alder M, Nummikoski P (1997) A feasibility study evaluating rhBMP-2/absorbable collagen sponge for maxillary sinus floor augmentation. Int J Periodontics Restorative Dent 17(1):11–25PubMedGoogle Scholar
  4. 4.
    Boyne PJ (2001) Application of bone morphogenetic proteins in the treatment of clinical oral and maxillofacial osseous defects. J Bone Joint Surg Am 83:146–150Google Scholar
  5. 5.
    Boyne PJ, Lilly LC, Marx RE, Moy PK, Nevins M, Spagnoli DB, Triplett RG (2005) De novo bone induction by recombinant human bone morphogenetic protein-2 (rhBMP-2) in maxillary sinus floor augmentation. J Oral Maxillofac Surg 63:1693–1707PubMedCrossRefGoogle Scholar
  6. 6.
    Burkus JK, Gornet MF, Dickman C, Zdeblick TA (2002) Anterior lumbar interbody fusion using rhBMP-2 with tapered interbody cages. J Spinal Disord Tech 15(5):337–349PubMedGoogle Scholar
  7. 7.
    Burkus JK, Heim SE, Gornet MF, Zdeblick TA (2003) Is INFUSE Bone Graft superior to autograft bone? An integrated analysis of clinical trials using the LT-CAGE lumbar tapered fusion device. J Spinal Disord Tech 16(2):113–122PubMedGoogle Scholar
  8. 8.
    Burkus JK, Sandhu HS, Gornet MF, Longley MC (2005) Use of rhBMP-2 in combination with structural cortical allografts: clinical and radiographic outcomes in anterior lumbar spinal surgery. J Bone Joint Surg Am 87(6):1205–1212PubMedCrossRefGoogle Scholar
  9. 9.
    Fiorellini JP, Howell TH, Cochran D, Malmquist J, Lilly LC, Spagnoli D, Toljanic J, Jones A, Nevins M (2005) Randomized study evaluating recombinant human bone morphogenetic protein-2 for extraction socket augmentation. J Periodontol 76(4):605–613PubMedCrossRefGoogle Scholar
  10. 10.
    Glassman SD, Carreon LC, Djurasovic M, Campbell MJ, Puno RM, Johnson JR, Dimar JR (2007) Posterolateral lumbar spine fusion with INFUSE Bone Graft. Spine J 7:44–49PubMedCrossRefGoogle Scholar
  11. 11.
    Haid RW, Branch CL Jr, Alexander JT, Burkus JK (2004) Posterior lumbar interbody fusion using recombinant human bone morphogenetic protein type 2 with cylindrical interbody cages. Spine J 4:527–539PubMedCrossRefGoogle Scholar
  12. 12.
    Jones AL, Bucholz RW, Bosse MJ, Mirza SK, Lyon TR, Webb LX, Pollak AN, Golden JD, Valentin-Opran A (2006) Recombinant human BMP-2 and allograft compared with autogenous bone graft for reconstruction of diaphyseal tibial fractures with cortical defects: a randomized, controlled trial. J Bone Joint Surg Am 88(7):1431–1441PubMedCrossRefGoogle Scholar
  13. 13.
    McKay B, Sandhu HS (2002) Use of recombinant human bone morphogenetic protein-2 in spinal fusion applications. Spine 27:S66–S85PubMedCrossRefGoogle Scholar
  14. 14.
    McKay WF, Peckham S, Scifert J (2006) Biologics to promote spinal fusion. In: Kurtz SM, Edidin AA (eds) Spine technology handbook. Elsevier Academic Press, Boston, Massachusetts, pp 241–279Google Scholar
  15. 15.
    Medtronic package insert no. M704819B001 (2007) INFUSE® Bone Graft for Certain Oral Maxillofacial and Dental Regenerative UsesGoogle Scholar
  16. 16.
    Mummaneni PV, Pan J, Haid RW, Rodts GE (2004) Contribution of recombinant human bone morphogenetic protein-2 to the rapid creation of interbody fusion when used in transforaminal lumbar interbody fusion: a preliminary report. J Neurosurg Spine 1:19–23PubMedCrossRefGoogle Scholar
  17. 17.
    Riedel GE, Valentin-Opran A (1999) Clinical evaluation of rhBMP-2/ACS in orthopedic trauma: a progress report. Orthopedics 22(7):663–665PubMedGoogle Scholar
  18. 18.
    Schwartz ND, Hicks BM (2006) Segmental bone defects treated using recombinant human bone morphogenetic protein. J Orthopaedics 3(2):e2Google Scholar
  19. 19.
    Schwender JD, Holly LT, Rouben DP, Foley KT (2005) Minimally invasive transforaminal lumbar interbody fusion (TLIF): technical feasibility and initial results. J Spinal Disord Tech 18:S1–S6PubMedCrossRefGoogle Scholar
  20. 20.
    Singh K, Smucker JD, Gill S, Boden SD (2006) Use of recombinant human bone morphogenetic protein-2 as an adjunct in posterolateral lumbar spine fusion: a prospective CT-scan analysis at one and two years. J Spinal Disord Tech 19(6):416–423PubMedCrossRefGoogle Scholar
  21. 21.
    Swiontkowski MF, Aro HT, Donell S, Esterhai JL, Goulet J, Jones A, Kregor PJ, Nordsletten L, Paiement G, Patel A (2006) Recombinant human bone morphogenetic protein-2 in open tibial fractures: a subgroup analysis of data combined from two prospective randomized studies. J Bone Joint Surg Am 88(6):1258–1265PubMedCrossRefGoogle Scholar
  22. 22.
    Wikesjö UME, Sorensen RG, Wozney JM (2001) Augmentation of alveolar bone and dental implant osseointegration: clinical implications of studies with rhBMP-2. J Bone Joint Surg Am 83(Suppl 1 Pt 2):S136–S145PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2007

Authors and Affiliations

  • William F. McKay
    • 1
  • Steven M. Peckham
    • 1
  • Jeffrey M. Badura
    • 1
  1. 1.Medtronic Spinal and BiologicsMemphisUSA

Personalised recommendations